Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases

Launched by UNIVERSITY OF ROCHESTER · Feb 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of living donor liver transplantation (LDLT) for patients with colorectal cancer that has spread to the liver, a condition known as metastatic colorectal cancer. The main goal of the study is to collect important information about these patients, including their health status and outcomes after the transplant. Researchers want to learn more about how this treatment can help people who cannot be treated with traditional surgery.

To participate in this trial, individuals must be at least 18 years old and have a specific type of colorectal cancer that cannot be removed with surgery. They also need to be eligible for the LDLT program at the University of Rochester. Participants will be asked to provide consent and will have their health data tracked throughout the study. This research is currently open for enrollment, and both men and women can join. If you or someone you know is facing this situation, this trial could offer valuable insights into a potential treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18
• • Non-amenable to curative hepatic resection as defined by FLR \<30%
• • Histologically confirmed adenocarcinoma of the colon or rectum
• • Candidate for LDLT for colorectal liver metastasis per the University of Rochester liver transplant program
• Exclusion Criteria:
• • Not a candidate of the LDLT liver transplant protocol for treatment of colorectal liver metastasis.
• • Unwilling to consent